“When you’re a hammer, everything looks like a nail.” Maslow’s famous line succinctly captures where many life sciences organizations find themselves with AI today. The hammer, in this case, is generative AI, an astonishingly powerful tool that seems to promise everything from accelerated molecule discovery to automated lab reporting. But as with any new instrument,…
Kythera Labs’ Wayfinder remasters incomplete medical data for AI analysis
Healthcare data is often incomplete and inconsistent, limiting efforts to improve patient outcomes and operational efficiency. A 2021 report from Sage Growth found that only 20% of healthcare organizations fully trust their data. Because records follow patients across providers with shifting identifiers and coding schemes, the same encounter often appears multiple times or partially, breaking…
How AI Is upgrading the drug hunter while driving leaner, meaner teams
AI isn’t some shiny new kid on the drug discovery block. In one way or another, it’s been lurking in labs for decades under aliases like computational chemistry and cheminformatics. The term ‘artificial intelligence’ itself dates back to the 1950s. Alister Campbell, vice president and global head of science and technology at Dotmatics, chuckles at…
Inside AION Labs, the AI-focused venture studio with the backing of AstraZeneca, Pfizer, AWS and other power players
Pharma R&D has a reputation for glacial change, but AI could finally force the industry to pivot. According to Deloitte’s 2024 Global Life Sciences Sector Outlook released in late May, only about 16% of drug discovery efforts were using AI, though it projected triple-digit growth over the next few years. “It’s definitely early,” says AION…
R&D Market Pulse: Volvo/Daimler embrace digital alliance, VW restructures, Toyota bets on AI
The R&D World Index (RDWI) for the week ending November 1, 2024, closed at 3,855.65 for the 25 companies in the RDWI. The Index was down -2.70% (or -107.16 basis points). Eight RDWI members gained value last week from 0.16% (Alibaba) to 8.36% (AbbVie). Seventeen RDWI members lost value the previous from -0.43% (Cisco) to…
This week in R&D: GM and Hyundai to partner on vehicle development, Moderna cuts $1.1B in R&D spending, and Fed interest rate decision
The R&D World Index (RDWI) for the week ending September 13, 2024, closed at 3,924.01 for the 25 companies in the RDWI. The Index was up 2.95% (or 112.59 basis points). Seventeen RDWI members gained value last week from 0.30% (Volkswagen AG) to 14.26% (Oracle). Eight RDWI members lost value the previous week from -0.85%…
This week in R&D: Eli Lilly eyes $1,000 share price while pharma overall cuts back on R&D
The R&D World Index (RDWI) climbed 2.57% this week, with Eli Lilly leading the charge at a 10.84% gain, while tech giants ramp up AI investments amidst regulatory challenges. In the week ending August 9, 2024, the index closed at 3768.96 for the 25 companies in the RDWI. The index was up 2.57% (or 94.45…